New York, NY – April 3, 2018 ‐ Bridge Medicines, a pioneering drug discovery company focused on
advancing promising early technologies from concept to clinic, announced today the appointment of
Louis M. Renzetti, Ph.D., as Chief Scientific Officer (CSO).
Bridge Medicines, launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University and
Weill Cornell Medicine, in partnership with Takeda Pharmaceutical Company Ltd., Deerfield
Management and Bay City Capital, is a groundbreaking initiative that extends the work of the
independent, non‐profit Tri‐Institutional Therapeutics Discovery Institute (Tri‐I TDI). Tri‐I TDI, also a
collaborative venture of the three academic institutions, in partnership with Takeda, is working on
approximately 50 early‐stage drug discovery projects spanning therapeutic areas that include infectious
disease, oncology, neuropsychiatry and rare diseases. As CSO of Bridge Medicines, Dr. Renzetti will be
responsible for scientific oversight for R&D programs within Bridge Medicines, building a portfolio of
early‐stage drug discovery projects and positioning these programs for entry into the clinic.
“We are thrilled to bring such a talented drug discovery expert as Louis into the role of CSO at Bridge
Medicines,” said William Polvino, CEO of Bridge Medicines. “Louis is a rigorously trained scientist and an
experienced drug developer. His skills in identifying promising scientific targets and driving toward
successful clinical products will be a great asset to the mission of Bridge Medicines, the Tri‐I TDI, and the
three institutions.”
Dr. Renzetti said, “Bridge Medicines is a unique opportunity to transform the breakthrough research
done at Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, and
the Tri‐I TDI into valuable medicines for patients. I am excited to join Bill and the team and look forward
to working with the highly talented investigators within the Tri‐Institutional community.”
Dr. Renzetti has more than 25 years of experience in biopharma, encompassing all aspects of drug
discovery and early development. Most recently, he served as Chief Research and Early Development
Officer for Gotham Therapeutics, a New York‐based start‐up. Prior to Gotham, Dr. Renzetti served as
SVP of Drug Discovery and Early Development at X‐Rx, Inc., where he led the company’s efforts to
develop small molecule inhibitors of autotaxin to treat fibrotic diseases, a program subsequently
partnered with Gilead. Dr. Renzetti spent much of his drug discovery career at Roche. He was the
champion and leader of the RNA Therapeutics division and collaboration with Alnylam. He served as the
Disease Biology Area Head for Inflammation, was VP of Respiratory and Inflammation, and head of
Discovery Pharmacology. Dr. Renzetti has advanced numerous programs to clinical candidacy and into
the clinic. He earned his doctorate in Physiology from the Lewis Katz School of Medicine at Temple
University and his Bachelor of Arts Degree from the University of Pennsylvania. Dr. Renzetti completed
his post‐doctoral training in Pharmacology at ICI Pharmaceuticals. He has authored more than 30
publications.
About Bridge Medicines
Bridge Medicines is a pioneering drug‐discovery company focused on advancing promising early
technologies in major academic institutions from human proof‐of‐concept to clinical development.
Launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine
and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management and Bay City
Capital, Bridge Medicines is a groundbreaking initiative that provides an unbroken, fully funded and
professionally staffed path from discovery to drug candidate.
Contacts:
Karen Heidelberger
Deerfield Management
karenh@deerfield.com
(212) 551‐1600
Carl S. Goldfischer, MD
Bay City Capital, LLC
carl@baycitycapital.com
(415) 835‐9385